Optimal Intensity for Oral Anticoagulation in Patients with Prosthetic Heart Valves Conferences

abstract

• SummaryAntithrombotic therapy in patients with heart valve replacement has been placed on a firm scientific footing based on a number of prospective clinical trials. Patients with bioprostheses in the mitral position require a minimal of 3 months oral anticoagulants at a target INR of 2.0-3.0. Patients with bioprostheses with additional risk factors should receive oral anticoagulants indefinitely. Patients with mechanical prostheses require life-long anticoagulants at a target INR of 2.5-3.5. The addition of antiplatelet drugs to anticoagulants improves the outcome particularly in patients at risk of vascular disease.

authors

• Turpie, Alexander Graham Gri

status

• published 

publication date

• July 1997

has subject area

• Cardiovascular System & Hematology (Science Metrix)

published in

• Hamostaseologie  Journal

keywords

• 32 Biomedical and Clinical Sciences
• 3201 Cardiovascular Medicine and Haematology
• 6 Evaluation of treatments and therapeutic interventions
• 6.1 Pharmaceuticals
• Assistive Technology
• Bioengineering
• Cardiovascular
• Heart Disease
• Hematology
• Rehabilitation

Digital Object Identifier (DOI)

• 10.1055/s-0038-1659982

start page

• 158

end page

• 160

volume

• 17

issue

• 03